The muscle spasticity market is estimated to be valued at US$ 4,167.6 million in 2023 and is expected to exhibit a CAGR of 8.9% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

 

Market Overview:

Muscle spasticity refers to a medical condition characterized by involuntary tightening or contracting of muscles. It is commonly seen in patients suffering from neurological conditions such as multiple sclerosis, cerebral palsy, stroke, and spinal cord injury. The spasticity treatment landscape has evolved significantly over the past decade with the approval and launch of new pharmaceutical treatment options. Currently, various oral, injectable and topical drugs are available for short-term and long-term management of muscle spasticity.

 

Market Dynamics:

Growing geriatric population is expected to drive the growth of muscle spasticity market over the forecast period. Rising life expectancy has resulted in exponential growth of the geriatric population worldwide. According to the World Health Organization (WHO), the global population aged 60 years and older is expected to grow by 56% to reach nearly 2.1 billion by 2050. Since age is a key risk factor for diseases that lead to spasticity like stroke and MS, increasing geriatric population base would elevate the patient pool for spasticity treatment. Additionally, there has been a rapid influx of novel therapeutic options approved in recent years including botulinum toxin injections and oral agents. Some of the major drugs launched in the past 5 years include Xeomin, Zhangtou and Corrid. This increasing availability of diverse treatment options has enabled improved management of disease symptoms and enhanced quality of life of patients.
 

Segment Analysis

The global muscle spasticity market is dominated by the spasticity in lower limbs segment. Muscle spasticity in lower limbs accounts for around 60% of the overall market share owing to the high prevalence of conditions affecting lower limbs such as cerebral palsy, multiple sclerosis and spinal cord injuries. Lower limb spasticity can lead to contractures and loss of mobility impacting overall motor functioning and quality of life.

 

PEST Analysis

Political: Regulations favoring the use of clinically approved treatments for muscle spasticity are driving market growth. Economic: Rising healthcare spending along with growing disposable income is fueling the demand for innovative treatment options. Social: Increasing patient awareness about the safe and effective management of muscle spasticity symptoms is a key factor. Technological: Advancements in drug delivery technologies for localized treatment and disease modifying drugs with novel mechanisms of action are expanding the market.

 

Key Takeaways

The Global Muscle Spasticity Market Demand is expected to witness high growth, exhibiting CAGR of 8.9% over the forecast period, due to increasing availability of advanced pharmacological treatment options.

The North American market holds the largest share owing to the significant prevalence of neurological disorders, favorable reimbursement policies, and availability of advanced healthcare facilities. The Asia Pacific region is projected to grow at the fastest pace during the forecast period.

Key players operating in the muscle spasticity market are Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc. These players are focusing on developing innovative treatment delivery formulations and devices.
 

Read More -   https://www.newsanalyticspro.com/muscle-spasticity-market-share-size-analysis-demand-and-trends-forecast/